VMQ StocksFor the value investor looking to harness academic research in
an actively managed portfolio
Bits and BipsNewsletter delivering insights on linking traditional finance, macro trends and cryptocurrency opportunities to help investors build stronger, more diversified portfolios.
All premium products come with free basic membership.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
NewAmsterdam Pharma Company N.V.'s fiscal Q4 earnings report was released on Wednesday, November 04. Let's dive in to see if (NAMS) missed or beat analyst's expectations.
As of Friday, October 23, NewAmsterdam Pharma Company N.V.’s NAMS share price has dipped by
5.33%, which has investors questioning if this is right time to buy.
As of Wednesday, September 30, NewAmsterdam Pharma Company N.V.’s NAMS share price has surged by
5.19%, which has investors questioning if this is right time to sell.
As of Thursday, September 17, NewAmsterdam Pharma Company N.V.’s NAMS share price has surged by
5.15%, which has investors questioning if this is right time to sell.
As of Wednesday, September 09, NewAmsterdam Pharma Company N.V.’s NAMS share price has dipped by
6.24%, which has investors questioning if this is right time to buy.
Rosalio Madrigal
Financial Summary
Share Statistics
NAMS
Industry Median
Percentile (All Stocks)
Market Cap (Mil)
$2,207.9
$203.5
57%
Shares Out (Mil)
124.1
55.2
66%
Institutional Ownership
98.9%
93.3%
83%
Float (Mil)
81.8
40.4
56%
Beta
0.14
1.05
10%
Avg Daily Volume (000s)
2,027
569
81%
Price Change (52-week)
(52.3%)
38.8%
21%
Growth
NAMS
Industry Median
Percentile (All Stocks)
Sales (5yr)
na
13.6%
na
Net Income (5yr)
(96.3%)
(10.7%)
2%
EPS (5yr)
(4.1%)
15.4%
26
Dividends (5yr)
na
0.0%
0%
Cash Flow (5yr)
(33.3%)
(15.7%)
17%
Estimates
Qtrly
Current Fiscal Year
Next Fiscal Year
# of Estimates
13
13
13
Current EPS
($0.462)
($1.481)
($2.028)
Month Ago EPS
($0.435)
($1.823)
($1.499)
# Rev Up
0
2
2
# Rev Down
1
1
1
Three Months Ago EPS
($0.441)
($1.818)
($1.479)
Year/Year Chg
230.0%
(13.9%)
(37.1%)
Financials
NAMS
Industry Median
Percentile (All Stocks)
Sales (TTM) (Mil)
$26
$40
15%
Net Income (TTM) (Mil)
($205)
($44)
6%
EPS (TTM)
($1.675)
($1.400)
16%
Operating Cash Flow (TTM) (Mil)
($151)
($35)
5%
Net Cash Flow (TTM) (Mil)
($115)
$-0
14%
Long-Term Debt (Q1) (Mil)
$0
$4
0%
Enterprise Value (Q1) (Mil)
$1,772
$142
48%
Valuation
NAMS
Industry Median
Percentile (All Stocks)
P/B
3.50
1.96
75%
P/E
na
16.9
na
Dividend Yield
0.0%
0.0%
0%
PEG (5yr hist)
na
0.9
na
Ratios
NAMS
Industry Median
Percentile (All Stocks)
Gross Margin
100.0%
67.6%
96%
Net Margin
(789.9%)
(50.8%)
0%
ROA
(27.8%)
(47.0%)
17%
ROE
(30.2%)
(51.8%)
20%
Liabilities to Assets
8.3%
29.6%
4%
F-Score
4
3
33%
NewAmsterdam Pharma Company N.V. did not pass any screens on 11/20/2026.
Looking for access to this powerful feature? Take the first step in becoming an A+ Investor today.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors